End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

por Castellsagué, X, Muñoz, N, Pitisuttithum, P, Ferris, D, Monsonego, J, Ault, K, Luna, J, Myers, E, Mallary, S, Bautista, O M, Bryan, J, Vuocolo, S, Haupt, R M, Saah, A
Publicado 2011